EFFLUX™ is a point-of-care acute kidney injury (AKI) monitoring device for hospital, medical, surgical and ICU patients. EFFLUX™ is the first in class point-of-care AKI detection device, which is revolutionizing the way ICU patients are treated, monitored and diagnosed. It is compact, lightweight, adjusts to fit any hospital bed, and comes with a user-friendly interface.
EFFLUX not only provides requisite early detection, it also provides on-going patient monitoring without the need to send numerous samples to the laboratory and having to wait for the results. This is made possible due to the nature of the device with real-time, point-of-care monitoring of numerous biomarkers. This provides physicians with the data stream necessary to manage patients that have quickly deteriorating kidney function complicated by the treatments being administered.
EFFLUX™ drastically changes the landscape, enabling healthcare providers to obtain critical data points from urine flow at their fingertips, that are both real-time and relevant to determining a patient's risk for AKI; results they are unable to achieve from current lab tests. Present-day systems involve arduous, time consuming, and laborious processes. The introduction of EFFLUX™ effectively makes these outdated procedures obsolete.
With a team with over a half century combined experience stemming from the largest medical device companies in the world, ARGUS International prides itself in excellence and ground breaking innovation. You can rest assured that our products will stand the test of time.
At ARGUS, we developed a life saving devices that help detect, monitor and alert physicians of patient impending risk of hospital acquired Acute Kidney Injury (AKI) and other conditions that are both common and costly issues for patients in hospital ICU's and post-operative environments. Our aim is save patients from End Stage Renal Disease (ESRD), lower hospital readmission and optimize patient outcome.
The ARGUS difference - state-of-the-art AKI detection and monitoring - EFFLUX ™. Accuracy you need in a point of care device. Information at your fingertips where it should be; not in a lab.
Chief Executive Officer & Chairman
Biomedical Engineer, Founder
Fmr. Secretary SFB and BMES Memphis Chapter
US Army Veteran, Sr. Research & Development Engineer
Chief Operations Officer
MBA Operations Management
3PL & 4PL Sourcing, Six Sigma, Manufacturing Processes,
Chief Financial Officer
BS. Applied Physics, Certified Public Accountant
Tax Consultant KPMG, State of Tennessee Auditor, Partner Advantage CPA Group LLC.
The University of Michigan has partnered with ARGUS International to perform the first EFFLUX clinical efficacy trials (Ongoing Now!).
Sign up to hear from us.
Copyright © 2019 ARGUS International - All Rights Reserved.